Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 1:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 1,955 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Standard protocol Clear all
Completed Not applicable Interventional

Prospective Evaluation of Silk Fibroin Incision Dressings in ACL Reconstruction

NCT07217613
View directory record Official record
Conditions
Anterior Cruciate Ligament Reconstruction
Interventions
silk fibroin-based incision dressing, cyanoacrylate-based closure system
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
14 Years to 60 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 21, 2026, 1:36 PM EDT
Completed Not applicable Interventional Results available

The Safety Evaluation of Silver Alginate (Algidex™) Dressing in Very Low Birth Weight (VLBW) Infants

NCT00593684
View directory record Official record
Conditions
Prematurity, Very Low Birth Weight
Interventions
Silver Alginate
Device
Lead sponsor
Baylor Research Institute
Other
Eligibility
Up to 72 Hours
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 21, 2026, 1:36 PM EDT
Recruiting Phase 3 Interventional

A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B

NCT07285460
View directory record Official record
Conditions
Hemophilia
Interventions
Fitusiran, Clotting factor concentrates (CFC) or bypassing agents (BPA), Antithrombin concentrate (ATIIIC)
Drug · Biological
Lead sponsor
Sanofi
Industry
Eligibility
1 Year to 11 Years · Male only
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
10
States / cities
Los Angeles, California • Orange, California • Torrance, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 21, 2026, 1:36 PM EDT
Active, not recruiting Phase 2 Interventional

Pilot Trial of Visual Healing® in Psilocybin-assisted Therapy for Alcohol Use Disorder

NCT04410913
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Psilocybin plus Visual Healing Set and Setting, Psilocybin plus Standard Set and Setting
Drug
Lead sponsor
Keith Heinzerling
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Jan 17, 2023 · Synced Oct 21, 2026, 1:36 PM EDT
Terminated Phase 4 Interventional Results available

Success of External Cephalic Version Study

NCT03106753
View directory record Official record
Conditions
External Cephalic Version
Interventions
Bupivacaine, Terbutaline
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 9, 2020 · Synced Oct 21, 2026, 1:36 PM EDT
Recruiting Phase 3 Interventional

Precision Ventilation vs Standard Care for Acute Respiratory Distress Syndrome

NCT06066502
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Respiratory Failure
Interventions
Precision ventilation, Guided usual care ventilation
Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
33
States / cities
Tucson, Arizona • Little Rock, Arkansas • La Jolla, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 21, 2026, 1:36 PM EDT
Active, not recruiting No phase listed Observational

Biomarkers of Immune-Related Toxicity

NCT03409016
View directory record Official record
Conditions
Cancer, Metastatic Cancer
Interventions
Blood Testing
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 100 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 21, 2026, 1:36 PM EDT
Active, not recruiting Not applicable Interventional

iExposure Intervention for Social Anxiety

NCT06409247
View directory record Official record
Conditions
Social Anxiety
Interventions
iExposure, iExposure plus attention guidance, iExposure plus attention control
Behavioral
Lead sponsor
Palo Alto University
Other
Eligibility
18 Years and older
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 21, 2026, 1:36 PM EDT
Active, not recruiting Phase 3 Interventional

RZ358 Treatment for Congenital Hyperinsulinism

NCT06208215
View directory record Official record
Conditions
Congenital Hyperinsulinism
Interventions
RZ358 (5 mg/kg) + SOC (Standard-of-Care) or Placebo + SOC, RZ358 (10 mg/kg) or Placebo + SOC, RZ358 (5-10 mg/kg) + SOC
Drug
Lead sponsor
Rezolute
Other
Eligibility
3 Months to 45 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 21, 2026, 1:36 PM EDT
Completed Not applicable Interventional

Home vs. Office Foley Catheter Removal in Women With Voiding Difficulty Following Pelvic Reconstructive Surgery

NCT03373773
View directory record Official record
Conditions
Voiding Disorders
Interventions
Foley catheter removal
Procedure
Lead sponsor
Yale University
Other
Eligibility
18 Years to 85 Years · Female only
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 29, 2022 · Synced Oct 21, 2026, 1:36 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

Rectal Acetaminophen Use During Oocyte Retrievals to Reduce Post-Operative Opioid Utilization

NCT03732469
View directory record Official record
Conditions
Opioid Use
Interventions
Acetaminophen, Fentanyl, Propofol
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 56 Years · Female only
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 18, 2021 · Synced Oct 21, 2026, 1:36 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Trial of the Ideal Protein System Versus Low Fat Diet for Weight Loss

NCT03515889
View directory record Official record
Conditions
Weight Loss
Interventions
Ideal Protein Weight Loss Method, Standard Weight Loss
Behavioral
Lead sponsor
Tulane University
Other
Eligibility
22 Years to 79 Years
Enrollment
192 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Bogalusa, Louisiana
Source: ClinicalTrials.gov public record
Updated Nov 22, 2024 · Synced Oct 21, 2026, 1:36 PM EDT
Completed Phase 1 Interventional

Dendritic Cell (DC) Vaccine for Malignant Glioma and Glioblastoma

NCT01808820
View directory record Official record
Conditions
Malignant Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma, High Grade Glioma
Interventions
Dendritic Cell Vaccine, Tumor Lysate, Imiquimod, Leukapheresis
Biological · Drug · Procedure
Lead sponsor
Macarena De La Fuente, MD
Other
Eligibility
13 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 20, 2022 · Synced Oct 21, 2026, 1:36 PM EDT
Completed Phase 2 Interventional Results available

COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Master Protocol

NCT04662086
View directory record Official record
Conditions
Covid19
Interventions
Acebilustat, Camostat
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Pleasanton, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 21, 2026, 1:36 PM EDT
Recruiting Phase 3 Interventional

Evaluation of Analgesia for Spine Fusion Elective Surgery in Children

NCT06626503
View directory record Official record
Conditions
Idiopathic Scoliosis
Interventions
Methadone based ERAS, Non-methadone based group
Drug
Lead sponsor
Senthil Sadhasivam
Other
Eligibility
10 Years to 18 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
4
States / cities
Indianapolis, Indiana • Cincinnati, Ohio • Pittsburgh, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 21, 2026, 1:36 PM EDT
Recruiting Phase 1 Interventional

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

NCT05091424
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Interventions
Mosunetuzumab, Tocilizumab, Venetoclax, Rituximab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
5
States / cities
Rochester, Minnesota • New York, New York • Columbus, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 21, 2026, 1:36 PM EDT
Active, not recruiting Not applicable Interventional

Relationship Checkups to Reduce Veteran Suicide Risk

NCT05525676
View directory record Official record
Conditions
Relationship Distress, Mental Health
Interventions
Brief Relationship Checkup (BRC), Co-Located Collaborative Care (CCC)
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Canandaigua, New York
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 21, 2026, 1:36 PM EDT
Completed No phase listed Observational

Carnitine, Aclycarnitine, Myocardial Function, and CRRT

NCT01941823
View directory record Official record
Conditions
Acute Renal Failure
Interventions
Not listed
Lead sponsor
Asha Moudgil
Other
Eligibility
1 Year to 21 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 23, 2020 · Synced Oct 21, 2026, 1:36 PM EDT
Completed Phase 2 Interventional Results available

Standard of Care +/- Midostaurin to Prevent Relapse Post Stem Cell Transplant in Patients With FLT3-ITD Mutated AML

NCT01883362
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Midostaurin, Standard of Care
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
18
States / cities
La Jolla, California • Los Angeles, California • Denver, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2021 · Synced Oct 21, 2026, 1:36 PM EDT
Completed Phase 2 Interventional Results available

Tocilizumab in Cardiac Transplantation

NCT03644667
View directory record Official record
Conditions
Heart Transplant
Interventions
tocilizumab, Placebo, Standard of Care Triple IS
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
20
States / cities
Beverly Hills, California • La Jolla, California • Stanford, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 21, 2026, 1:36 PM EDT
Recruiting No phase listed Observational

Nutritional Impacts of Palynziq on Patients With Phenylketonuria (PKU)

NCT04404530
View directory record Official record
Conditions
Phenylketonurias
Interventions
Palynziq
Drug
Lead sponsor
Emory University
Other
Eligibility
16 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 21, 2026, 1:36 PM EDT
Terminated Phase 2 Interventional Results available

AflacLL1901 (CHOA-AML)

NCT04326439
View directory record Official record
Conditions
Acute Myeloid Leukemia, AML, Childhood
Interventions
Cytarabine, Daunorubicin, Erwinase, Etoposide, Gemtuzumab ozogamicin, Stem cell transplantation (SCT), Sorafenib
Drug · Procedure
Lead sponsor
Emory University
Other
Eligibility
Up to 21 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 15, 2022 · Synced Oct 21, 2026, 1:36 PM EDT
Terminated Not applicable Interventional Results available

Effect of Moderate Caloric Restriction on Glomerular Growth After Kidney Transplantation

NCT03607500
View directory record Official record
Conditions
Kidney Transplant; Complications, Glomerular Disease, Weight Gain, Kidney Transplant
Interventions
caloric intake reduction
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 21, 2026, 1:36 PM EDT
Completed Phase 1 Interventional

Islet Transplantation in Type 1 Diabetic Patients

NCT00214253
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Thiazolidinedione
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 31, 2017 · Synced Oct 21, 2026, 1:36 PM EDT